APIE Therapeutics Welcomes Jim Greenwood to its Board of Directors
Retrieved on:
Tuesday, March 21, 2023
APJ, BIO, Greenwood, Politics, Senior counsel, Policy, Pennsylvania House of Representatives, Energy, 21st Century Cures Act, William Maclay (Pennsylvania senator), Science, Bachelor of Arts in Organizational Psychology, Pennsylvania State Senate, 2002 Pennsylvania House of Representatives election, Representative, Patient, Biotechnology Innovation Organization, Dickinson College, Louisiana House of Representatives, Piper, Therapy, Health, DLA Piper, Social work, House, Fine chemical, Pharmaceutical industry
Cary, NC, March 21, 2023 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced the appointment of Jim Greenwood , former president & CEO of the Biotechnology Innovation Organization (BIO), to its board of directors.
Key Points:
- Cary, NC, March 21, 2023 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced the appointment of Jim Greenwood , former president & CEO of the Biotechnology Innovation Organization (BIO), to its board of directors.
- “We have a strong team of directors and advisors who have expertise in the development of medications for lung diseases and the care of patients.
- During his 18-year tenure as president and CEO of BIO, Jim built bipartisan support for the drug industry.
- “APIE possesses these key attributes, and that’s why I’m excited to join the team.”